CDER Lists Planned Guidances for 2019

Drug Industry Daily
A A
CDER plans to release 93 new or revised guidances for drugmakers in 2019, spelling out the center’s current thinking on issues ranging from risk-benefit assessments for opioids to exclusivity periods for generics.

To View This Article:

Login

Subscribe To Drug Industry Daily